0001493152-22-005399.txt : 20220224 0001493152-22-005399.hdr.sgml : 20220224 20220224161544 ACCESSION NUMBER: 0001493152-22-005399 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20220222 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220224 DATE AS OF CHANGE: 20220224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PAVmed Inc. CENTRAL INDEX KEY: 0001624326 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 471214177 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37685 FILM NUMBER: 22671142 BUSINESS ADDRESS: STREET 1: ONE GRAND CENTRAL PLACE STREET 2: SUITE 4600 CITY: NEW YORK STATE: NY ZIP: 10165 BUSINESS PHONE: 212-949-4319 MAIL ADDRESS: STREET 1: ONE GRAND CENTRAL PLACE STREET 2: SUITE 4600 CITY: NEW YORK STATE: NY ZIP: 10165 FORMER COMPANY: FORMER CONFORMED NAME: PAXmed Inc. DATE OF NAME CHANGE: 20141105 8-K 1 form8-k.htm
0001624326 false 0001624326 2022-02-22 2022-02-22 0001624326 PAVM:CommonStockParValue0.01PerShareMember 2022-02-22 2022-02-22 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2022-02-22 2022-02-22 0001624326 PAVM:SeriesWWarrantsToPurchaseCommonStockMember 2022-02-22 2022-02-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 22, 2022

 

PAVMED INC.

 

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-37685   47-1214177

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

One Grand Central Place, Suite 4600, New York, New York   10165
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (212) 949-4319

 

N/A

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, Par Value $0.01 Per Share   PAVM   The Nasdaq Stock Market LLC
Series Z Warrants to Purchase Common Stock   PAVMZ   The Nasdaq Stock Market LLC
Series W Warrants to Purchase Common Stock   PAVMW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers.

 

On February 22, 2022, the board of directors (the “Board”) of PAVmed Inc. (the “Company”) appointed Shaun O’Neil as the Company’s Chief Operating Officer.

 

Mr. O’Neil, 39, has been serving as the Company’s Chief Commercial Officer and Executive Vice President of Business Development since July 2018, and has also served as the Chief Commercial Officer of Lucid Diagnostics Inc. (NASD: LUCD), the Company’s majority owned subsidiary, since July 2018. Previously, from June 2011 to July 2018, Mr. O’Neil served in various roles of increasing responsibility for AngioDynamics (NASD: ANGO), first as Product Manager, then as Senior Product Manager and finally as Regional Business Manager. Before joining AngioDynamics, from October 2005 to June 2011, Mr. O’Neil served as a Product Manager and Sales and Service Engineer for Aycan Medical Systems. Mr. O’Neil earned his bachelor’s degree in business administration from Alfred University in 2004 and his master’s degree in business administration from Rochester Institute of Technology in 2011. Mr. O’Neil has not engaged in any transactions with the Company that are required to be reported pursuant to Item 404(a) of Regulation S-K.

 

On February 22, 2022, in connection with Mr. O’Neil’s appointment, the Company entered into an employment agreement (an “Employment Agreement”) with him.

 

The Employment Agreement provides for an initial term that expires on February 22, 2025, which will automatically renew for additional one-year terms, unless either the Company or Mr. O’Neil provides notice of non-renewal at least 60 days prior to the end of the then-current term. The Employment Agreement provides for an annual base salary of $325,000 and an annual performance bonus of up to 50% of his base salary in the preceding fiscal year, upon meeting certain objectives as determined by the Board or the compensation committee of the Board.

 

In accordance with the Employment Agreement, the Company granted Mr. O’Neil a stock option award (the “Option”) to acquire 300,000 shares (the “Option Shares”) of the Company’s common stock under the Company’s 2014 Long-Term Incentive Plan. The Option has an exercise price of per share of $1.48, equal to the closing price of the Company’s common stock as of the date immediately prior to the date of the grant. The Option shall become exercisable as to 1/12 of the Option Shares on March 31, 2022 and shall become exercisable as to 1/12 of the Option Shares on the last day of each successive fiscal quarter for the following 11 fiscal quarters.

 

The Company may terminate Mr. O’Neil’s employment with “cause” (as such term is defined in the Employment Agreement) or without cause upon 30 days’ notice. Mr. O’Neil may terminate his employment with “good reason” (as such term is defined in the Employment Agreement) or without good reason upon 30 days’ notice to the Company. If Mr. O’Neil’s employment is terminated by the Company without cause or by him with good reason, he is entitled to receive his base salary through the date of termination and for a period of 12 months thereafter, a pro rata portion of his current year target bonus amount, all valid expense reimbursements, health insurance coverage for up to 12 months, and all accrued but unused vacation pay. If Mr. O’Neil’s employment is terminated due to his death or disability, he is entitled to his base salary through the date of termination, a pro rata portion of any current year target bonus amount, all earned but unpaid prior year annual bonuses, all valid expense reimbursements, and all accrued but unused vacation pay. If Mr. O’Neil’s employment is terminated by the Company with cause or by him without good reason, he will be entitled only to his base salary through the date of termination, all valid expense reimbursements and certain accrued but unused vacation pay.

 

The Employment Agreement contains provisions protecting the Company’s confidential information and contains provisions restricting Mr. O’Neil’s ability to compete with the Company during his employment and for a period of one year (or two years in the case of a change of control) thereafter. The non-compete provisions generally impose restrictions on (i) employment by, rendering services to, engaging in, or owning an interest in any competing business, (ii) employing or retaining employees or service providers of the Company and (iii) soliciting or accepting business from the Company’s customers or business partners for the benefit of a competing business, subject to certain conditions and limitations.

 

The Company also entered into its standard form of indemnification agreement with Mr. O’Neil.

 

 

 

 

The foregoing description of the Employment Agreement is not complete and is qualified in its entirety by reference to full text of the Employment Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

 

Item 7.01 Regulation FD Disclosure.

 

On February 24, 2022, the Company issued a press release announcing Mr. O’Neil’s appointment. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information set forth under this Item 7.01, including the exhibit hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (“Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
10.1   Employment Agreement with Shaun O’Neil
99.1   Press Release
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 24, 2022 PAVMED INC.
     
  By: /s/ Dennis McGrath
    Dennis McGrath
    President and Chief Financial Officer

 

 

 

EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of February 22, 2022 is entered into between Shaun O’Neil (“Executive”), and PAVmed Inc., a Delaware corporation having its principal office at One Grand Central Place, Suite 4600, New York, New York 10165 (“Company”) to become effective immediately.

 

WHEREAS, the Company and the Executive desire to enter into this Agreement to set forth the terms and conditions of Executive’s employment with the Company.

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements hereinafter set forth, the Company and the Executive hereby agree as follows:

 

1. Employment, Duties and Acceptance.

 

1.1 General. The Company hereby agrees to employ the Executive as its Chief Operating Officer and Executive Vice President. All of Executive’s powers and authority in any capacity shall at all times be subject to the direction and control of the Company’s Chief Executive Officer (“CEO”). The Executive may be assigned such management and supervisory responsibilities and executive duties for the Company or any subsidiary of the Company, including serving as an executive officer and/or director of any subsidiary, as are consistent with Executive’s status as Chief Operating Officer and Executive Vice President.

 

1.2 Full-Time Position. Executive accepts such employment and agrees to devote his best efforts and full time to promote the business and affairs of the Company and its affiliated entities and shall be engaged in other business activities only to the extent that such activities do not materially interfere or conflict with his obligations to the Company hereunder. Nothing herein, other than Section 5.4 below, shall be construed as preventing Executive from making and supervising personal investments, or serving on civic, philanthropic, educational, or charitable boards or committees, or with the prior written consent of the Board, in its sole discretion, on either public or private corporate boards so long as such activities are not restricted under the Company’s Code of Conduct and employment practices. Executive acknowledges and agrees that Schedule 1.2 attached hereto represents a complete list of corporate boards on which the Executive serves as of the effective date of this agreement. Notwithstanding any provision of this Section to the contrary, in no event shall the Executive invest in any business competitive with the Company or that would otherwise violate the provisions of Section 5.4 below.

 

 

 

 

1.3 Location. Executive will perform his duties in San Diego County, California or in such other location as may be mutually agreed by Executive and the Company. Executive shall undertake such travel, within or outside the United States, as is necessary to perform his duties hereunder.

 

2. Term. The initial term of this Agreement shall commence on February 22, 2022 (“Effective Date”) and terminate on the third anniversary of the Effective Date (the “Initial Term”) unless terminated earlier as provided in this Agreement. In addition, the term of this Agreement shall thereafter automatically renew for periods of one-year (the “Renewal Term”) unless either party gives written notice to the other party at least 60 days prior to the end of the term or at least 60 days prior to any one-year renewal period, that the Agreement shall not be further extended. The period commencing on the Effective Date and ending on the date on which the term of the Executive’s employment under the Agreement terminates is referred to herein as the “Term”.

 

3. Compensation and Benefits.

 

3.1 Salary. The Company shall pay to Executive a salary (“Base Salary”) at the annual rate of $325,000. Executive’s compensation shall be paid in equal, periodic installments in accordance with the Company’s normal payroll procedures. The Executive’s base salary shall be reviewed periodically by the Board or Committee (as defined below) pursuant to the Board or Committee’s normal performance review policies for senior level executives.

 

3.2 Bonus. In addition to the Base Salary, Executive shall be eligible to receive a discretionary performance bonus (“Bonus”) with a target of fifty percent (50%) of the Executive’s Base Salary in effect as of December 31st of the preceding year based on Executive’s and the Company’s performance over the preceding year. The payment and amount of any Bonus shall be in the sole discretion of the Board or the Compensation Committee of the Board (the “Committee”).

 

 

 

 

3.3 Equity Awards. Subject to approval by the Committee, Executive will be granted an option (the “Option”) to acquire 300,000 shares of the Company’s common stock, at an exercise price per share basis equal to the closing price of the Company’s common stock as of the date immediately prior to the date of grant (the “Grant Date”). Such option will be subject to the terms and conditions of the Company’s 2014 Long-Term Incentive Equity Plan and a stock option agreement in the Company’s standard form (pursuant to which the Option shall be granted).

 

3.4 Benefits. Executive shall be entitled to such medical, life, disability and other benefits as are generally afforded to other executives of the Company, subject to applicable waiting periods and other conditions, as well as participation in all other company-wide employee benefits, including a defined contribution pension plan and 401(k) plan, as may be made available generally to executive employees from time to time. The Executive shall be eligible to participate in the Company’s annual and long-term incentive plans and programs in accordance with the terms of such plans and programs as in effect and afforded to other senior executives of the Company at levels determined by the Board (or committee of the Board).

 

3.5 Vacation. Executive shall be entitled to twenty (20) days of paid vacation in each year during the Term and to a reasonable number of other days off for religious and personal reasons in accordance with customary Company policy.

 

3.6 Expenses. The Company shall pay or reimburse Executive for all transportation, hotel and other expenses reasonably incurred by Executive on business trips and for all other ordinary and reasonable out-of-pocket expenses actually incurred by him in the conduct of the business of the Company, including expenses relating to his laptop, cell phone or other similar devices, against itemized vouchers submitted with respect to any such expenses and approved in accordance with customary procedures.

 

4. Termination.

 

4.1 Death. If Executive dies during the Term, Executive’s employment hereunder shall terminate and the Company shall pay to Executive’s estate the amount set forth in Section 4.6(a).

 

 

 

 

4.2 Disability. The Company, by written notice to Executive, may terminate Executive’s employment hereunder if Executive shall fail because of illness or incapacity to render services of the character contemplated by this Agreement for one hundred eighty (180) days. Upon such termination, the Company shall pay to Executive the amount set forth in Section 4.6(a).

 

4.3 By Company for “Cause” or By the Executive Without “Good Reason”. The Company, by written notice to Executive, may terminate Executive’s employment hereunder for “Cause.” As used herein, “Cause” shall mean: (a) the refusal or failure by Executive to carry out any lawful direction of the Board which are of a material nature and consistent with his status as Chief Operating Officer and Executive Vice President (or whichever positions Executive holds at such time), or the refusal or failure by Executive to perform a material part of Executive’s duties hereunder; (b) the commission by Executive of a material breach of any of the provisions of this Agreement; (c) fraud or dishonest action by Executive in his relations with the Company or any of its subsidiaries or affiliates (“dishonest” for these purposes shall mean Executive’s knowingly or recklessly making of a material misstatement or omission for his personal benefit); or (d) the conviction of Executive of a felony under federal or state law. Notwithstanding the foregoing, no “Cause” for termination shall be deemed to exist with respect to Executive’s acts described in clauses (a) or (b) above, unless the Company shall have given written notice to Executive within a period not to exceed thirty (30) calendar days of the initial existence of the occurrence, specifying the “Cause” with reasonable particularity and, within thirty (30) calendar days after such notice, Executive shall not have cured or eliminated the problem or thing giving rise to such “Cause;” provided, however, no more than two cure periods need be provided during any twelve-month period. Upon such termination, the Company shall pay to Executive the amount set forth in Section 4.6(b). The Company shall also pay such amount to Executive upon his termination of employment without “Good Reason” (as defined below), which Executive shall have the right to do on at least thirty (30) days written notice to the Company.

 

 

 

 

4.4 By Executive for “Good Reason”. The Executive, by written notice to the Company, may terminate Executive’s employment hereunder if a “Good Reason” exists. For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following circumstances without the Executive’s prior written consent: (a) a substantial and material adverse change in the nature of Executive’s title, duties or responsibilities with the Company (other than as a director of the Company) that represents a demotion from his title, duties or responsibilities as in effect immediately prior to such change (such change, a “Demotion”); (b) material breach of this Agreement by the Company; (c) a failure by the Company to make any payment to Executive when due, unless the payment is not material and is being contested by the Company, in good faith; (d) a change of the principal office or work place assigned to the Executive to a location more than 35 miles distant from its location immediately prior to such change; (e) a material reduction of the Executive’s Base Salary or bonus opportunity, unless pursuant to a reduction in such items applicable proportionally to all senior management and board members; or (f) a liquidation, bankruptcy or receivership of the Company. Notwithstanding the foregoing, no “Good Reason” shall be deemed to exist with respect to the Company’s acts described in clauses (a), (b), (c), (d) or (e) above, unless Executive shall have given written notice to the Company within a period not to exceed thirty (30) calendar days of the initial existence of the occurrence, specifying the “Good Reason” with reasonable particularity and, within thirty (30) calendar days after such notice, the Company shall not have cured or eliminated the problem or thing giving rise to such “Good Reason”; provided, however, that no more than two cure periods shall be provided during any twelve-month period of a breach of clauses (a), (b), (c), (d), or (e) above. Upon such termination, the Company shall pay to Executive the amount set forth in Section 4.6(c).

 

4.5 By Company Without “Cause”. The Company may terminate Executive’s employment hereunder without “Cause” by giving at least thirty (30) days written notice to Executive. Upon such termination, the Company shall pay to Executive the amount set forth in Section 4.6(c).

 

4.6 Compensation Upon Termination. In the event that Executive’s employment hereunder is terminated, the Company shall pay to Executive the following compensation:

 

(a) Payment Upon Death or Disability. In the event that Executive’s employment is terminated pursuant to Sections 4.1 or 4.2, the Company shall no longer be under any obligation to Executive or his legal representatives pursuant to this Agreement except for: (i) the Base Salary due Executive pursuant to Section 3.1 hereof through the date of termination; (ii) any Bonus which would have become payable under Section 3.2 for the year in which the employment was terminated prorated by multiplying the full amount of the Bonus by a fraction, the numerator of which is the number of “full calendar months” worked by Executive during the year of termination and the denominator of which is 12 (a “full calendar month” is a month in which the Executive worked at least two weeks); (iii) all earned and previously approved but unpaid Bonuses for any year prior to the year of termination; (iv) all valid expense reimbursements, and (v) all unused vacation pay through the date of termination required by law to be paid.

 

 

 

 

(b) Payment Upon Termination by the Company For “Cause” or by the Executive Without Good Reason. In the event that the Company terminates Executive’s employment hereunder pursuant to Section 4.3, the Company shall have no further obligations to the Executive hereunder, except for: (i) the Base Salary due Executive pursuant to Section 3.1 hereof through the date of termination (ii) all valid expense reimbursements and (iii) all unused vacation pay through the date of termination required by law to be paid.

 

(c) Payment Upon Termination by Company Without Cause or by Executive for Good Reason. In the event that Executive’s employment is terminated pursuant to Sections 4.4 or 4.5, the Company shall have no further obligations to Executive hereunder except for: (i) the Base Salary (at the rate in effect immediately before Executive’s termination or resignation, as applicable) due Executive pursuant to Section 3.1 hereof for twelve (12) months from the date of termination; (ii) any Bonus which would have become payable under Section 3.2 for the year in which the employment was terminated prorated by multiplying the full amount of the Bonus by a fraction, the numerator of which is the number of “full calendar months” worked by Executive during the year of termination and the denominator of which is 12 (a “full calendar month” is a month in which the Executive worked at least two weeks); (iii) the Base Salary due Executive pursuant to Section 3.1 hereof through the date of termination; (iv) all valid expense reimbursements; (v) to the extent the Executive timely elects to receive continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay or reimburse the Executive, on a monthly basis, an amount equal to the full monthly premium for such coverage, from the date of termination until the earlier of (a) the date twelve (12) months following the date of termination, and (B) the date of Executive becoming eligible for coverage under a new employer’s health insurance plan (the COBRA health care continuation coverage period under Section 4980B of the Internal Revenue Code of 1986, as amended (the “Code”) shall run concurrently with the foregoing period); and (vi) all unused vacation pay through the date of termination required by law to be paid, subject, in the case of clause (i) and (ii), to Executive’s compliance with Section 5 and to Executive’s execution of a release of claims in favor of the Company, its affiliates and their respective officers and directors in a form provided by the Company and such release becoming effective,.

 

 

 

 

(d) Executive shall have no duty to mitigate awards paid or payable to him pursuant to this Agreement, and any compensation paid or payable to Executive from sources other than the Company will not offset or terminate the Company’s obligation to pay to Executive the full amounts pursuant to this Agreement.

 

5. Protection of Confidential Information; Non-Competition.

 

5.1 Acknowledgment. Executive acknowledges that:

 

(a) As a result of his employment with the Company, Executive will obtain secret and confidential information concerning the business of the Company and its subsidiaries (referred to collectively in this Section 5 as the “Company”), including, without limitation, financial information, proprietary rights, trade secrets and “know-how,” customers and sources (“Confidential Information”).

 

(b) The Company will suffer substantial damage which will be difficult to compute if, during the period of his employment with the Company or thereafter, Executive should enter a business competitive with the Company or divulge Confidential Information.

 

(c) The provisions of this Agreement are reasonable and necessary for the protection of the business of the Company.

 

5.2 Confidentiality. Executive agrees that he will not at any time, during the Term or thereafter, divulge to any person or entity any Confidential Information obtained or learned by him as a result of his employment with the Company, except (i) in the course of performing his duties hereunder, (ii) with the Company’s prior written consent; (iii) to the extent that any such information is in the public domain other than as a result of Executive’s breach of any of his obligations hereunder; or (iv) where required to be disclosed by law, regulation, stock exchange rule, court order, subpoena or other government process. If Executive shall be required to make disclosure pursuant to the provisions of clause (iv) of the preceding sentence, Executive promptly, but in no event more than 48 hours after learning of such subpoena, court order, or other government process, shall notify, confirmed by mail, the Company and, at the Company’s expense, Executive shall: (a) take all reasonably necessary and lawful steps required by the Company to defend against the enforcement of such subpoena, court order or other government process, and (b) permit the Company to intervene and participate with counsel of its choice in any proceeding relating to the enforcement thereof.

 

 

 

 

5.3 Documents. Upon termination of his employment with the Company, Executive will promptly deliver to the Company all memoranda, notes, records, reports, manuals, drawings, blueprints and other documents (and all copies thereof) relating to the business of the Company and all property associated therewith, which he may then possess or have under his control; provided, however, that Executive shall be entitled to retain copies of such documents reasonably necessary to document his financial relationship with the Company.

 

5.4 Non-competition. During the Term and for a period of one (1) year thereafter, or two (2) years thereafter in the event of a Change of Control, Executive, without the prior written permission of the Company, shall not, anywhere in the world, (i) be employed by, or render any services to, any person, firm or corporation engaged in the medical device industry (or any other business) which is directly in competition with any “material” business conducted or proposed to be conducted by the Company or any of its subsidiaries at the time of termination (“Competitive Business”); (ii) engage in any Competitive Business for his own account; (iii) be associated with or interested in any Competitive Business as an individual, partner, shareholder, creditor, director, officer, principal, agent, employee, trustee, consultant, advisor or in any other relationship or capacity; (iv) employ or retain, or have or cause any other person or entity to employ or retain, any person who was employed or retained by the Company while Executive was employed by the Company; or (v) solicit, interfere with, or endeavor to entice away from the Company, for the benefit of a Competitive Business, any of its customers or other persons with whom the Company has a contractual relationship. Notwithstanding the foregoing, nothing in this Agreement shall preclude Executive from investing his personal assets in any manner he chooses, provided, however, that Executive may not, during the period referred to in this Section 5.4, own more than 4.9% of the equity securities of any Competitive Business.

 

 

 

 

5.5 Injunctive Relief. If Executive commits a breach, or threatens to commit a breach, of any of the provisions of Sections 5.2 or 5.4, the Company shall have the right and remedy to seek to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed by Executive that the services being rendered hereunder to the Company are of a special, unique and extraordinary character and that any such breach or threatened breach will cause irreparable injury to the Company and that money damages will not provide an adequate remedy to the Company. The rights and remedies enumerated in this Section 5.5 shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or equity. In connection with any legal action or proceeding arising out of or relating to this Agreement, the prevailing party in such action or proceeding shall be entitled to be reimbursed by the other party for the reasonable attorneys’ fees and costs incurred by the prevailing party.

 

5.6 Modification. If any provision of Sections 5.2 or 5.4 is held to be unenforceable because of the scope, duration or area of its applicability, the tribunal making such determination shall have the power to modify such scope, duration, or area, or all of them, and such provision or provisions shall then be applicable in such modified form.

 

5.7 Survival. The provisions of this Section 5 shall survive the termination of employment under this Agreement for any reason.

 

6. Miscellaneous Provisions.

 

6.1 Notices. All notices provided for in this Agreement shall be in writing, and shall be deemed to have been duly given when (i) delivered personally to the party to receive the same, or (ii) when mailed first class postage prepaid, by certified mail, return receipt requested, addressed to the party to receive the same at his or its address set forth below, or such other address as the party to receive the same shall have specified by written notice given in the manner provided for in this Section 6.1, or sent via email or facsimile.

 

If to Executive, to his address as set forth in the Company’s books and records.

 

If to the Company:

 

PAVmed Inc.

One Grand Central Place, Suite 4600

New York, New York 10165

Attn: Lishan Aklog, M.D.

Email: la@pavmed.com

 

With a copy in either case to:

 

Friedman Kaplan Seiler and Adelman LLP

7 Times Square

New York, NY 10036-6516

Attn: Michael Gordon

Email: mgordon@fklaw.com

 

 

 

 

6.2 Entire Agreement; Waiver. This Agreement, the Option and the separate indemnification agreement being entered simultaneously herewith sets forth the entire agreement of the parties relating to the employment of Executive and is intended to supersede all prior negotiations, understandings and agreements. No provisions of this Agreement may be waived or changed except by a writing by the party against whom such waiver or change is sought to be enforced. The failure of any party to require performance of any provision hereof or thereof shall in no manner affect the right at a later time to enforce such provision.

 

6.3 Governing Law. All questions with respect to the construction of this Agreement, and the rights and obligations of the parties hereunder, shall be determined in accordance with the law of the State of New York applicable to agreements made and to be performed entirely in New York.

 

6.4 Binding Effect; Nonassignability. This Agreement shall inure to the benefit of and be binding upon the successors and assigns of the Company. This Agreement shall not be assignable by Executive, but shall inure to the benefit of and be binding upon Executive’s heirs and legal representatives.

 

6.5 Severability. Should any provision of this Agreement become legally unenforceable, no other provision of this Agreement shall be affected, and this Agreement shall continue as if the Agreement had been executed absent the unenforceable provision.

 

6.6 Section 409A. This Agreement is intended to comply with the provisions of Section 409A of the Internal Revenue Code (“Section 409A”). To the extent that any payments and/or benefits provided hereunder are not considered compliant with Section 409A, the parties agree that the Company shall take all actions necessary to make such payments and/or benefits become compliant.

 

 

 

 

6.7 Preparation of Agreement. This Agreement has been prepared by Friedman Kaplan Seiler & Adelman LLP (“Friedman Kaplan”) solely as counsel to the Company. Friedman Kaplan is not acting as legal counsel nor providing any legal representation or consultative services to Executive in connection with the Agreement and the Company has advised Executive to seek the advice of other counsel in connection with the negotiation and preparation of this Agreement.

 

7. Arbitration; Expenses. In the event of any dispute under the provisions of this Agreement, other than a dispute in which the primary relief sought is an equitable remedy such as an injunction, the parties shall be required to have the dispute, controversy or claim settled by arbitration in the non-moving parties jurisdiction in accordance with the Employment Arbitration Rules and Mediation Procedures then in effect of the American Arbitration Association, before an arbitrator agreed to by both parties. If the parties cannot agree upon the choice of arbitrator, the Company and the Executive will each choose an arbitrator. The two arbitrators will then select a third arbitrator who will serve as the actual arbitrator for the dispute, controversy or claim. Any award entered by the arbitrator shall be final, binding and nonappealable and judgment may be entered thereon by either party in accordance with applicable law in any court of competent jurisdiction. This arbitration provision shall be specifically enforceable. The arbitrator shall have no authority to modify any provision of this Agreement or to award a remedy for a dispute involving this Agreement other than a benefit specifically provided under or by virtue of the Agreement. Each party shall be responsible for its own expenses relating to the conduct of the arbitration (including reasonable attorneys’ fees and expenses) and shall share the fees of the American Arbitration Association.

 

8. Attorneys’ Fees. Except as provided in Section 7 above, in any action at law or in equity to enforce or construe any provisions or rights under this Agreement, the unsuccessful party or parties to such litigation, as determined by the courts pursuant to a final judgment or decree, shall pay the successful party or parties all costs, expenses, and reasonable attorneys’ fees incurred by such successful party or parties (including, without limitation, such costs, expenses, and fees on any appeals), and if such successful party or parties shall recover judgment in any such action or proceedings, such costs, expenses, and attorneys’ fees shall be included as part of such judgment.

 

[Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above written.

 

  PAVMED INC.
     
  By: /s/ Lishan Aklog
  Name: Lishan Aklog, M.D.
  Title: Chairman and CEO

 

  By: /s/ Shaun O’Neil
  Name: Shaun O’Neil

 

 
 

 

Schedule 1.2. Schedule of Consultancy, Advisory, or Board of Directors

None.

 

 

EX-99.1 3 ex99-1.htm

 

Exhibit 99.1

 

 

PAVmed Appoints Shaun O’Neil as Chief Operating Officer

 

NEW YORK, February 24, 2022 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the appointment of Shaun O’Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O’Neil has served as PAVmed’s Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company’s Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities Exchange Act of 1934.

 

“Mr. O’Neil has been an invaluable member of our company and its leadership team since joining us nearly four years ago, including playing a central role in our transition to a commercial enterprise,” said Lishan Aklog M.D., PAVmed’s Chairman and Chief Executive Officer. “He has built a solid and rapidly expanding commercial infrastructure—including sales, marketing, and market access—most notably for Lucid and its products, as well as nascent commercial teams for other commercial and near-commercial products. He has also played important roles in numerous other critical corporate initiatives, including the launch of our Lucid Test Center network, our transition to a dedicated CLIA-certified laboratory and in various business development activities. His deep involvement in operational and commercial activities across the breadth of the company make him the ideal candidate to serve as our inaugural COO, a position launched to accommodate our rapid growth to nearly one hundred employees over the past year.”

 

“I am energized to take on this expanded role at such an exciting time for PAVmed and its subsidiaries,” said Mr. O’Neil. “We are in as strong a position as ever to execute on our strategic plan, drive commercialization of our products and grow long-term shareholder value. That strength is built on a solid balance sheet, groundbreaking technologies, and the best team in the industry. I look forward helping execute on our vision to transform PAVmed into a leading global medical technology company.”

 

Mr. O’Neil has served as PAVmed’s Chief Commercial Officer and Executive Vice President, Business Development since 2018. Prior to PAVmed, Mr. O’Neil brought to PAVmed more than fifteen years of sales and marketing leadership, and product and business development expertise in both startup and established companies, including a particularly strong track record in growing sales and increasing market share for innovative medical devices. From 2011 to 2018 Mr. O’Neil held various sales and marketing leadership positions with AngioDynamics (Nasdaq: ANGO), a leading provider of innovative medical devices used by interventional radiologists, interventional cardiologists, surgeons, and other physicians for the minimally invasive diagnosis and treatment of cancer and peripheral vascular disease. Prior to AngioDynamics, he served in various sales, marketing and engineering roles at Aycan Medical Systems, a privately held medical imaging company, Harris Interactive and Quality Solutions Group. Mr. O’Neil received a bachelor’s degree in Business Administration from Alfred University and an M.B.A. from the Rochester Institute of Technology.

 

 
 

 

About PAVmed

 

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. PAVmed’s CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome is currently in limited commercial release. The product pipeline also includes the EsoCure™ Esophageal Ablation Device with Caldus™ Technology, which complements EsoGuard and EsoCheck, the NextFlo™ Intravenous Infusion Set, the PortIO™ Implantable Intraosseous Vascular Access Device, novel pediatric ear tubes, mechanical circulatory support technology and glucose monitoring. For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and Instagram.

 

Forward-Looking Statements

 

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s common stock; PAVmed’s Series W and Series Z warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s clinical and preclinical studies; whether and when PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s and products once cleared and commercialized; PAVmed’s ability to raise additional funding as needed; and other competitive developments. In addition, PAVmed has been monitoring the COVID-19 pandemic and the pandemic’s impact on PAVmed’s businesses. PAVmed expects the significance of the COVID-19 pandemic, including the extent of its effect on its financial and operational results, to be dictated by, among other things, the success of efforts to contain the pandemic and the impact of such efforts on PAVmed’s businesses. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s future operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report filed with the Securities and Exchange Commission. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

 

Contacts

 

Investors

Adrian K. Miller

PAVmed Inc.

AKM@PAVmed.com

 

Media

Shani Lewis

LaVoieHealthScience

(609) 516-5761

PAVmed@lavoiehealthscience.com

 

 

 

GRAPHIC 4 logo_002.jpg begin 644 logo_002.jpg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ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 6 pavm-20220222.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 7 pavm-20220222_def.xml XBRL DEFINITION FILE EX-101.LAB 8 pavm-20220222_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, Par Value $0.01 Per Share Series Z Warrants to Purchase Common Stock Series W Warrants to Purchase Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 9 pavm-20220222_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Feb. 22, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 22, 2022
Entity File Number 001-37685
Entity Registrant Name PAVMED INC.
Entity Central Index Key 0001624326
Entity Tax Identification Number 47-1214177
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One One Grand Central Place
Entity Address, Address Line Two Suite 4600
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10165
City Area Code (212)
Local Phone Number 949-4319
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, Par Value $0.01 Per Share  
Title of 12(b) Security Common Stock, Par Value $0.01 Per Share
Trading Symbol PAVM
Security Exchange Name NASDAQ
Series Z Warrants to Purchase Common Stock  
Title of 12(b) Security Series Z Warrants to Purchase Common Stock
Trading Symbol PAVMZ
Security Exchange Name NASDAQ
Series W Warrants to Purchase Common Stock  
Title of 12(b) Security Series W Warrants to Purchase Common Stock
Trading Symbol PAVMW
Security Exchange Name NASDAQ
XML 11 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001624326 2022-02-22 2022-02-22 0001624326 PAVM:CommonStockParValue0.01PerShareMember 2022-02-22 2022-02-22 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2022-02-22 2022-02-22 0001624326 PAVM:SeriesWWarrantsToPurchaseCommonStockMember 2022-02-22 2022-02-22 iso4217:USD shares iso4217:USD shares 0001624326 false 8-K 2022-02-22 PAVMED INC. DE 001-37685 47-1214177 One Grand Central Place Suite 4600 New York NY 10165 (212) 949-4319 false false false false Common Stock, Par Value $0.01 Per Share PAVM NASDAQ Series Z Warrants to Purchase Common Stock PAVMZ NASDAQ Series W Warrants to Purchase Common Stock PAVMW NASDAQ false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /6!6%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #U@5A4D%&ULS9)1 M2\,P$,>_BN2]O295D=#E9<,G!<&!XEM(;EM8DX;DI-VWMZU;A^@'\#%W__SN M=W"-B=)T"5]2%S&1PWPS^#9D:>**'8BB!,CF@%[GHC9' MO4<0574/'DE;31HF8!$7(E.--=(DU-2E,]Z:!1\_4SO#K %LT6.@#+SDP-0T M,9Z&MH$K8((1)I^_"V@7XES]$SMW@)V30W9+JN_[LJ_GW+@#A_?GI]=YW<*% M3#H8'']E)^D4<<4ND]_J]6;[R)2HA"@J48C;K>"2W\GZX6-R_>%W%?:==3OW MCXTO@JJ!7W>AO@!02P,$% @ ]8%85)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #U@5A4T$Y?;,($ ""%0 & 'AL+W=O?PD+WL"NU)78HM"N*1"G=0[MEN<*UVKZ9Q(#5)&9MI[3? M_L8!$JX7)O3:AQ(GF7]^\4S^'KF]4OK)+(2PY"6.$G-96UB[_%JOFV A8FY. MU5(D<&6F=,PM#/6\;I9:\# +BJ,Z\[QF/>8RJ77:V;F1[K15:B.9B)$F)HUC MKE^O1*16ES5:VYZXD_.%=2?JG?:2S\58V+^7(PVC>JX2RE@D1JJ$:#&[K'7I MURO?=P'9'?=2K,S.,7&O,E7JR0T&X67-9LJ-Z*GH089V<5D[KY%0S'@:V3NU^E-L7NC,Z04J,ME_ MLEK?VVC42) :J^)-,!#$,EG_\I?-1.P&M/8$L$T R[C7#\HHK[GEG;96*Z+= MW:#F#K)7S:(!3B8N*V.KX:J$.-OIJ6>AVW4+4NY$/=B$7:W#V)ZP&S$])8P= M$^8Q]N_P.A#D&"S'8)F>OT?O6@4IY-J2R>M2E.'@X>/R,1T8@'(V<&5MFDZ^O2I(E%G.=L9 MJMA/K+2OY$9&@@S3>%I>/+B&Y]$3O]4\/T-XFCE/\Q">.S&7QFH.DS;D<>E, MX3JC[OUM__IH,.R=(E2MG*IU"%4/DJAY1 9)*%[(=_%:QH4K>3!93=;P61/! M.L^QS@_!FO 7,@B!3!=Y'@7A^ -DD#II=(9 MV3$96RA]HC3IJ12F$V95A:4)QL6O^P@A]0J[] YA[(:A%L8<;P_(#[B/_$Q* MP2HD(>J(P-\W*-\PKYE1Q /,3.B.P]/_CSQ9J5)D7'*<2LA)H^EY&&%A_A2W M[[>$/3>"C$_4*BFEP^6&T O\@EX 8RO6!(J;^ENVO!Q'6CW+Y&V.-H"XYO 7 MAE8L$Q1W][=H(V4L5,ZC7.[]1BH4*9@-YLJT6"8H[O%9"KO0)^Y'P04^,\J^ M8"C%"D%Q:_^A O<]+52"+5D5(A>-BY.&3R\PHF)UH+BI/VAIK4A@:N(X338> M;$JI<*&JCH,6*P/%C7RL(AE(*Y,YN84"UY)'I3RX2B5/L110W*Y'6IP$,#T" MOK!U8PB]F=#DYVRV)W^X7A49*U8 AMOU?\@&QJ1 5@58(5L)6/@].\CO^['0 M *_XIK<\R@5Y _OU*.N MW27C!=?HLPKC9KC)3J2%'E7-"&6?IU_(6 0I?';E[X\KK:FS-?HCY(6O,]R% M)YJ'+G'CUWBJ2C_#"@'7S&(DA8LSW(2WDT;Z+\&")W.QM[NN$!IVQ]?=OS"F MPLX9[L1C,"=AR"-YX-HU_(9814:I!D CR&Z%88\KO)KA%ON>,L*5UN!9&7T0 MOG!UAOOQ 96$"[A*>L10"D-GN &_HY1PHRX1?&[.,^ M^HY2JE#:*:4/PA?6[>/675U*%0*NE!XPE)UM&MR/#R^E"J']I53?V5%SNY.W MW*VEAD1B!DK>:0OL3J\W_-8#JY;9)MM46:OB[' A.#0$[@:X/E/*;@=NWR[? M=NW\ U!+ P04 " #U@5A4X/0ZB:H" P# #0 'AL+W-T>6QE&:.9N:,9F235>/.DC\>.7>D4U(W:WITKGZ?),WAR!5KWIB::X^4 MQBKFO&JKI*DM9T4#3DHFB]DL2Q03FFY6NE4[Y1IR,*UV:SJCR695&GVQI#08 M_%*F.#DQN:9;)L7>BGXM4T*>@WD!AH.1QA+GJ? UG8.E>0[P/&C 2T(M/!;2!0*FCZ D-8@@3%(A_'2W$O@K[]J_"DEJ,/EI>BZ_6NG/)CT>=X=%;7\OQ!BDHK'FK_[82;%1O]R-%8\>RS MP:0*:6R:O2?O1CS-.AEF\ M&OB;<9^L!!XK:_H5GE;RPH'L6R&=T(-V%$7!]8NI]^$=V_O'X4U\O[[@)6NE M>YK -;W(7W@A6I5/JQY@7X95%_DSG.YY-CW3?"ZA"][Q8CNHMMKW(O&"SSI< MX'"/[/HKCF ^ 8LC@&%Y, :83_#"\OQ+]2S1>@*&<5M&D27JLT1]@E<,V?8? M+$_<)_=7O-(\3],LPW9TNXTRV&+[EF7PC4?#N($'E@X]W&)^3U.6!>PV8'\\3PP4W&?-(6N8MRP$XPC M>8XA,(OQ&-8?20$3;8T.P M6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<- M!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW M,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]Z MUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV, MIDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .; MO\P>=0>6N=6RKV' M5[+E&''\GN4/4$L#!!0 ( /6!6%0D'INBK0 /@! : >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S M(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[. MXS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " #U@5A499!YDAD! #/ P $P %M# M;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK M_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBN MM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F MI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S! M9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8 MYL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( /6!6%0' M04UB@0 +$ 0 " 0 !D;V-0&UL M4$L! A0#% @ ]8%85)!7*??O *P( !$ ( !KP M &1O8U!R;W!S+V-O&UL4$L! A0#% @ ]8%85)E&PO=V]R M:W-H965T&UL4$L! A0#% @ ]8%85.#T.HFJ @ , P M T ( !!@T 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ ]8%85"0>FZ*M ^ $ !H M ( !)!( 'AL+U]R96QS+W=O9(9 0 SP, !, ( !"1, %M# G;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ 4Q0 end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 4 122 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pavmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex10-1.htm ex99-1.htm pavm-20220222.xsd pavm-20220222_def.xml pavm-20220222_lab.xml pavm-20220222_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "pavm-20220222_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "pavm-20220222_lab.xml" ] }, "presentationLink": { "local": [ "pavm-20220222_pre.xml" ] }, "schema": { "local": [ "pavm-20220222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 3, "memberStandard": 0, "nsprefix": "PAVM", "nsuri": "http://pavmed.com/20220222", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-02-22to2022-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://pavmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-02-22to2022-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "PAVM_CommonStockParValue0.01PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Par Value $0.01 Per Share" } } }, "localname": "CommonStockParValue0.01PerShareMember", "nsuri": "http://pavmed.com/20220222", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "PAVM_SeriesWWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series W Warrants to Purchase Common Stock" } } }, "localname": "SeriesWWarrantsToPurchaseCommonStockMember", "nsuri": "http://pavmed.com/20220222", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "PAVM_SeriesZWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series Z Warrants to Purchase Common Stock" } } }, "localname": "SeriesZWarrantsToPurchaseCommonStockMember", "nsuri": "http://pavmed.com/20220222", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 18 0001493152-22-005399-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-005399-xbrl.zip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end